Although our results revealed that mTORC1‐targeted therapy may serve as a potential option for chordoma with abnormal RAB3B/p‐S6 hyperactivation, the immunosuppressive properties remain a potential obstacle to the clinical application of mTORC1 inhibition in cancer therapy. This evidence concerns the gene RPS6 and chordoma.